Bacterial ghosts as carriers of protein subunit and DNA-encoded antigens for vaccine applications

Expert Review of Vaccines

Volumn 11, Issue 1, 2012, Pages 97-116

  Muhammad, Abbas ^a   Champeimont, Jonathan ^a   Mayr, Ulrike Beate ^b   Lubitz, Werner ^a,b   Kudela, Pavol ^b,c  

^a UNIVERSITY OF VIENNA   (Austria)

^b BIRD C GmbHandCoKG ^*  (Austria)

^c CANCER RESEARCH INSTITUTE   (Slovakia)

Author keywords

antigen delivery system; bacterial ghosts; natural adjuvant; vaccine

Indexed keywords

AMINOGLYCOSIDE ANTIBIOTIC AGENT; ANTIGEN; BACTERIAL GHOST VACCINE; BACTERIAL VACCINE; BETA LACTAM ANTIBIOTIC; DNA VACCINE; PENICILLIN G; PLASMID DNA; UNCLASSIFIED DRUG;

BACTERIAL GHOST; BACTERIAL MEMBRANE; CELLULAR IMMUNITY; DRUG DELIVERY SYSTEM; GENE EXPRESSION; HUMAN; HUMORAL IMMUNITY; IMMUNIZATION; IMMUNOCONTRACEPTION; MEMBRANE VESICLE; NONHUMAN; PRIORITY JOURNAL; REVIEW; VACCINE PRODUCTION;

ANIMALS; BACTERIA; CELL MEMBRANE; DRUG DELIVERY SYSTEMS; HUMANS; LIPOSOMES; VACCINATION; VACCINES, DNA; VACCINES, SUBUNIT;

EID: 83155164600     PISSN: 14760584     EISSN: 17448395     Source Type: Journal    
DOI: 10.1586/erv.11.149     Document Type: Review

References (145)

1. Winkelstein W Jr. Not just a country doctor: Edward Jenner, scientist. Epidemiol. Rev. 14, 1-15 (1992).
2. Willis NJ. Edward Jenner and the eradication of smallpox. Scott. Med. J. 42(4), 118-121 (1997). (Pubitemid 27390271)
3. Jalava K, Hensel A, Szostak M, Resch S, Lubitz W. Bacterial ghosts as vaccine candidates for veterinary applications. J. Cont. Rel. 85(1-3), 17-25 (2002). (Pubitemid 35452635)
4. Kaminski RW, Oaks EV. Inactivated and subunit vaccines to prevent shigellosis. Expert Rev. Vaccines 8(12), 1693-1704 (2009).
5. Leroux-Roels G. Unmet needs in modern vaccinology: adjuvants to improve the immune response. Vaccine 28(Suppl. 3), C25-C36 (2010).
6. Patel JR, Heldens JG. Immunoprophylaxis against important virus disease of horses, farm animals and birds. Vaccine 27(12), 1797-1810 (2009).
7. Silva AJ, Eko FO, Benitez JA. Exploiting cholera vaccines as a versatile antigen delivery platform. Biotechnol. Lett. 30(4), 571-579 (2008).
8. Walker RI, Steele D, Aguado T. Analysis of strategies to successfully vaccinate infants in developing countries against enterotoxigenic E. coli (ETEC) disease. Vaccine 25(14), 2545-2566 (2007). (Pubitemid 46400935)
9. Zepp F. Principles of vaccine design-lessons from nature. Vaccine 28(Suppl. 3), C14-C24 (2010).
10. Ito Y. A tumor-producing factor extracted by phenol from papillomatous tissue (Shope) of cottontail rabbits. Virology 12, 596-601 (1960).
11. Liu MA, Wahren B, Karlsson Hedestam GB. DNA vaccines: recent developments and future possibilities. Hum. Gene Ther. 17(11), 1051-1061 (2006). (Pubitemid 44749708)
12. Wolff JA, Malone RW, Williams P et al. Direct gene transfer into mouse muscle in vivo. Science 247(4949 Pt 1), 1465-1468 (1990).
13. Dhama K, Mahendran M, Gupta PK, Rai A. DNA vaccines and their applications in veterinary practice: current perspectives. Vet. Res. Commun. 32(5), 341-356 (2008).
14. Babiuk S, Tsang C, van Drunen Littel-van den Hurk S, Babiuk LA, Griebel PJ. A single HBsAg DNA vaccination in combination with electroporation elicits long-term antibody responses in sheep. Bioelectrochemistry 70(2), 269-274 (2007). (Pubitemid 46507978)
15. Oshop GL, Elankumaran S, Heckert RA. DNA vaccination in the avian. Vet. Immunol. Immunopathol. 89(1-2), 1-12 (2002).
16. Dunham SP. The application of nucleic acid vaccines in veterinary medicine. Res. Vet. Sci. 73(1), 9-16 (2002). (Pubitemid 35174505)
17. Wiendl H, Hohlfeld R, Kieseier BC. Immunobiology of muscle: advances in understanding an immunological microenvironment. Trends Immunol. 26(7), 373-380 (2005). (Pubitemid 40835843)
18. Nagaraju K. Immunological capabilities of skeletal muscle cells. Acta Physiol. Scand. 171(3), 215-223 (2001). (Pubitemid 32823789)
19. Paukner S, Kudela P, Kohl G, Schlapp T, Friedrichs S, Lubitz W. DNA-loaded bacterial ghosts efficiently mediate reporter gene transfer and expression in macrophages. Mol. Ther. 11(2), 215-223 (2005).
20. Gurunathan S, Klinman DM, Seder RA. DNA vaccines: immunology, application, and optimization. Ann. Rev. Immunol. 18, 927-974 (2000). (Pubitemid 30365401)
21. Henriksen-Lacey M, Korsholm KS, Andersen P, Perrie Y, Christensen D. Liposomal vaccine delivery systems. Exp. Opin. Drug Deliv. 8(4), 505-519 (2011).
22. Arias JL, Clares B, Morales ME, Gallardo V, Ruiz MA. Lipid-based drug delivery systems for cancer treatment. Curr. Drug Targets 12(8), 1151-1165 (2011).
23. Poirier VJ, Thamm DH, Kurzman ID et al. Liposome-encapsulated doxorubicin (Doxil) and doxorubicin in the treatment of vaccine-associated sarcoma in cats. J. Vet. Intern. Med. 16(6), 726-731 (2002). (Pubitemid 135748369)
24. Marr AK, Kurzman ID, Vail DM. Preclinical evaluation of a liposome-encapsulated formulation of cisplatin in clinically normal dogs. Am. J. Vet. Res. 65(11), 1474-1478 (2004). (Pubitemid 39561986)
25. U'Ren LW, Biller BJ, Elmslie RE, Thamm DH, Dow SW. Evaluation of a novel tumor vaccine in dogs with hemangiosarcoma. J. Vet. Intern. Med. 21(1), 113-120 (2007).
26. Thiele L, Rothen-Rutishauser B, Jilek S, Wunderli-Allenspach H, Merkle HP, Walter E. Evaluation of particle uptake in human blood monocyte-derived cells in vitro. Does phagocytosis activity of dendritic cells measure up with macrophages? J. Cont. Rel. 76(1-2), 59-71 (2001). (Pubitemid 32786885)
27. Zaks K, Jordan M, Guth A et al. Efficient immunization and cross-priming by vaccine adjuvants containing TLR3 or TLR9 agonists complexed to cationic liposomes. J. Immunol. 176(12), 7335-7345 (2006). (Pubitemid 43849034)
28. Tanaka T, Legat A, Adam E et al. DiC14-amidine cationic liposomes stimulate myeloid dendritic cells through Toll-like receptor 4. Eur. J. Immunol. 38(5), 1351-1357 (2008).
29. Didierlaurent AM, Morel S, Lockman L et al. AS04, an aluminum salt- and TLR4 agonist-based adjuvant system, induces a transient localized innate immune response leading to enhanced adaptive immunity. J. Immunol. 183(10), 6186-6197 (2009).
30. Bachmann MF, Jennings GT. Vaccine delivery: a matter of size, geometry, kinetics and molecular patterns. Nat. Rev. Immunol. 10(11), 787-796 (2010).
31. Mutwiri G, Gerdts V, van Drunen Littel-van den Hurk S et al. Combination adjuvants: the next generation of adjuvants? Expert Rev. Vaccines 10(1), 95-107 (2011).
32. Wagner H. Bacterial CpG DNA activates immune cells to signal infectious danger. Adv. Immunol. 73, 329-368 (1999). (Pubitemid 29300433)
33. Klinman DM. Immunotherapeutic uses of CpG oligodeoxynucleotides. Nat. Rev. Immunol. 4(4), 249-258 (2004). (Pubitemid 38478660)
34. Krieg AM. CpG motifs in bacterial DNA and their immune effects. Ann. Rev. Immunol. 20, 709-760 (2002). (Pubitemid 34293438)
35. US FDA. Guidance for Industry: Guidance for Human Somatic Cell Therapy and Gene Therapy. US Department of Health and Human Services, Food and Drug Administration, Center for Biologics Evaluation and Research, Rockville, MD, USA (1998).
36. EMEA. Overview of Comments Received on Guideline on the Non-clinical Studies Required Prior to Clinical Use of Gene Therapy Medicinal Products. EMEA/ CHMP/GTWP/65260/2008. European Medicines Agency, London, UK (2008).
37. EMEA. Guideline on the Non-clinical Studies Required Prior to Clinical Use of Gene Therapy Medicinal Products. EMEA/ CHMP/GTWP/125459/2006. European Medicines Agency, London, UK (2008).
38. EMEA. Note for Guidance on the Quality, Preclinical and Clinical Aspects of Gene Transfer. CPMP/BWP/3088/99. European Medicines Agency, London, UK (2001).
39. Calarota SA, Weiner DB. Enhancement of human immunodeficiency virus type 1-DNA vaccine potency through incorporation of T-helper 1 molecular adjuvants. Immunol. Rev. 199, 84-99 (2004). (Pubitemid 38736766)
40. Scheerlinck JY. Genetic adjuvants for DNA vaccines. Vaccine 19(17-19), 2647-2656 (2001).
41. Garver KA, LaPatra SE, Kurath G. Efficacy of an infectious hematopoietic necrosis (IHN) virus DNA vaccine in Chinook Oncorhynchus tshawytscha and sockeye O. nerka salmon. Dis. Aquat. Organ. 64(1), 13-22 (2005). (Pubitemid 40641108)
42. Davidson AH, Traub-Dargatz JL, Rodeheaver RM et al. Immunologic responses to West Nile virus in vaccinated and clinically affected horses. J. Am. Vet. Med. Assoc. 226(2), 240-245 (2005). (Pubitemid 40123299)
43. Davis EG, Zhang Y, Tuttle J, Hankins K, Wilkerson M. Investigation of antigen specific lymphocyte responses in healthy horses vaccinated with an inactivated West Nile virus vaccine. Vet. Immunol. Immunopathol. 126(3-4), 293-301 (2008).
44. Bergman PJ, Camps-Palau MA, McKnight JA et al. Development of a xenogeneic DNA vaccine program for canine malignant melanoma at the animal medical center. Vaccine 24(21), 4582-4585 (2006). (Pubitemid 44218845)
45. Thacker EL, Holtkamp DJ, Khan AS, Brown PA, Draghia-Akli R. Plasmid-mediated growth hormone-releasing hormone efficacy in reducing disease associated with Mycoplasma hyopneumoniae and porcine reproductive and respiratory syndrome virus infection. J. Anim. Sci. 84(3), 733-742 (2006). (Pubitemid 44405688)
46. Liu MA. Immunologic basis of vaccine vectors. Immunity 33(4), 504-515 (2010).
47. Tabrizi CA, Walcher P, Mayr UB et al. Bacterial ghosts - biological particles as delivery systems for antigens, nucleic acids and drugs. Curr. Opin. Biotechnol. 15(6), 530-537 (2004). (Pubitemid 39551005)
48. Lubitz W, Witte A, Eko FO et al. Extended recombinant bacterial ghost system. J. Biotechnol. 73(2-3), 261-273 (1999). (Pubitemid 29376457)
49. Szostak MP, Hensel A, Eko FO et al. Bacterial ghosts: non-living candidate vaccines. J. Biotechnol. 44(1-3), 161-170 (1996). (Pubitemid 26059097)
50. Szostak M, Lubitz W. Recombinant bacterial ghosts as multivaccine vehicles. In: Vaccines 91: Modern Approaches to New Vaccines Including Prevention of AIDS. Chanock R (Ed.). Cold Spring Harbor Laboratory Press, NY, USA 409-414 (1991).
51. Lubitz P, Mayr UB, Lubitz W. Applications of bacterial ghosts in biomedicine. Adv. Exp. Med. Biol. 655, 159-170 (2009).
52. Mayr B, Koller VJ, Lubitz P, Lubitz W. Bacterial Ghosts as Vaccine and Drug Delivery Platforms. Sleator R, Hill C (Eds). Landes Bioscience, Austin, TX, USA (2008).
53. Witte A, Wanner G, Blasi U, Halfmann G, Szostak M, Lubitz W. Endogenous transmembrane tunnel formation mediated by phi X174 lysis protein E. J. Bacteriol. 172(7), 4109-4114 (1990). (Pubitemid 20213400)
54. Huter V, Szostak MP, Gampfer J et al. Bacterial ghosts as drug carrier and targeting vehicles. J. Cont. Rel. 61(1-2), 51-63 (1999). (Pubitemid 29406079)
55. Paukner S, Kohl G, Jalava K, Lubitz W. Sealed bacterial ghosts - novel targeting vehicles for advanced drug delivery of water-soluble substances. J. Drug Target 11(3), 151-161 (2003). (Pubitemid 37236328)
56. Witte A, Wanner G, Sulzner M, Lubitz W. Dynamics of PhiX174 protein E-mediated lysis of Escherichia coli. Arch. Microbiol. 157(4), 381-388 (1992).
57. Riedmann EM, Kyd JM, Cripps AW, Lubitz W. Bacterial ghosts as adjuvant particles. Expert Rev. Vaccines 6(2), 241-253 (2007). (Pubitemid 46607459)
58. Langemann T, Koller VJ, Muhammad A, Kudela P, Mayr UB, Lubitz W. The bacterial ghost platform system: production and applications. Bioeng. Bugs 1(5), 326-336 (2010).
59. Ebensen T, Paukner S, Link C et al. Bacterial ghosts are an efficient delivery system for DNA vaccines. J. Immunol. 172(11), 6858-6865 (2004). (Pubitemid 38669124)
60. Eko FO, Lubitz W, McMillan L et al. Recombinant Vibrio cholerae ghosts as a delivery vehicle for vaccinating against Chlamydia trachomatis. Vaccine 21(15), 1694-1703 (2003). (Pubitemid 36292160)
61. Eko FO, Mayr UB, Attridge SR, Lubitz W. Characterization and immunogenicity of Vibrio cholerae ghosts expressing toxin-coregulated pili. J. Biotechnol. 83(1-2), 115-123 (2000).
62. Eko FO, Schukovskaya T, Lotzmanova EY et al. Evaluation of the protective efficacy of Vibrio cholerae ghost (VCG) candidate vaccines in rabbits. Vaccine 21(25-26), 3663-3674 (2003). (Pubitemid 37338191)
63. Ekong EE, Okenu DN, Mania-Pramanik J et al. A Vibrio cholerae ghost-based subunit vaccine induces cross-protective chlamydial immunity that is enhanced by CTA2B, the nontoxic derivative of cholera toxin. FEMS Immunol. Med. Microbiol. 55(2), 280-291 (2009).
64. Hensel A, Huter V, Katinger A et al. Intramuscular immunization with genetically inactivated (ghosts) Actinobacillus pleuropneumoniae serotype 9 protects pigs against homologous aerosol challenge and prevents carrier state. Vaccine 18(26), 2945-2955 (2000). (Pubitemid 30303796)
65. Huter V, Hensel A, Brand E, Lubitz W. Improved protection against lung colonization by Actinobacillus pleuropneumoniae ghosts: characterization of a genetically inactivated vaccine. J. Biotechnol. 83(1-2), 161-172 (2000).
66. Jechlinger W, Haller C, Resch S, Hofmann A, Szostak MP, Lubitz W. Comparative immunogenicity of the hepatitis B virus core 149 antigen displayed on the inner and outer membrane of bacterial ghosts. Vaccine 23(27), 3609-3617 (2005). (Pubitemid 40602796)
67. Katinger A, Lubitz W, Szostak MP et al. Pigs aerogenously immunized with genetically inactivated (ghosts) or irradiated Actinobacillus pleuropneumoniae are protected against a homologous aerosol challenge despite differing in pulmonary cellular and antibody responses. J. Biotechnol. 73(2-3), 251-260 (1999). (Pubitemid 29376456)
68. Marchart J, Rehagen M, Dropmann G et al. Protective immunity against pasteurellosis in cattle, induced by Pasteurella haemolytica ghosts. Vaccine 21(13-14), 1415-1422 (2003). (Pubitemid 36263183)
69. Mayr UB, Haller C, Haidinger W et al. Bacterial ghosts as an oral vaccine: a single dose of Escherichia coli O157:H7 bacterial ghosts protects mice against lethal challenge. Infect. Immun. 73(8), 4810-4817 (2005). (Pubitemid 41105637)
70. Walcher P, Cui X, Arrow JA et al. Bacterial ghosts as a delivery system for zona pellucida-2 fertility control vaccines for brushtail possums (Trichosurus vulpecula). Vaccine 26(52), 6832-6838 (2008).
71. Eko FO, Hensel A, Bunka S, Lubitz W. Immunogenicity of Vibrio cholerae ghosts following intraperitoneal immunization of mice. Vaccine 12(14), 1330-1334 (1994). (Pubitemid 24325733)
72. Eko FO, Okenu DN, Singh UP, He Q, Black C, Igietseme JU. Evaluation of a broadly protective Chlamydia-cholera combination vaccine candidate. Vaccine 29(21), 3802-3810 (2011).
73. Jechlinger W, Szostak MP, Witte A, Lubitz W. Altered temperature induction sensitivity of the lambda pR/cI857 system for controlled gene E expression in Escherichia coli. FEMS Microbiol. Lett. 173(2), 347-352 (1999). (Pubitemid 29146137)
74. Witte A, Blasi U, Halfmann G, Szostak M, Wanner G, Lubitz W. Phi X174 protein E-mediated lysis of Escherichia coli. Biochimie 72(2-3), 191-200 (1990).
75. Witte A, Lubitz W. Biochemical characterization of phi X174-protein-E-mediated lysis of Escherichia coli. Eur. J. Biochem. 180(2), 393-398 (1989). (Pubitemid 19088830)
76. Blasi U, Henrich B, Lubitz W. Lysis of Escherichia coli by cloned phi X174 gene E depends on its expression. J. Gen. Microbiol. 131(5), 1107-1114 (1985). (Pubitemid 15028284)
77. Henrich B, Lubitz W, Plapp R. Lysis of Escherichia coli by induction of cloned phi X174 genes. Mol. Gen. Genet. 185(3), 493-497 (1982). (Pubitemid 12008170)
78. Mayr UB, Walcher P, Azimpour C, Riedmann E, Haller C, Lubitz W. Bacterial ghosts as antigen delivery vehicles. Adv. Drug Deliv. Rev. 57(9), 1381-1391 (2005). (Pubitemid 40791117)
79. Jalava K, Eko FO, Riedmann E, Lubitz W. Bacterial ghosts as carrier and targeting systems for mucosal antigen delivery. Expert Rev. Vaccines 2(1), 45-51 (2003). (Pubitemid 36559938)
80. Lubitz W, Pugsley AP. Changes in host cell phospholipid composition of øX174 gene E product. FEMS Microbiol. Lett. 30(1-2), 171-175 (1985). (Pubitemid 16231502)
81. Witte A, Lubitz W, Bakker EP. Proton-motive-force-dependent step in the pathway to lysis of Escherichia coli induced by bacteriophage phi X174 gene E product. J. Bacteriol. 169(4), 1750-1752 (1987). (Pubitemid 17063512)
82. Lubitz W, Halfmann G, Plapp R. Lysis of Escherichia coli after infection with phiX174 depends on the regulation of the cellular autolytic system. J. Gen. Microbiol. 130(Pt 5), 1079-1087 (1984). (Pubitemid 14114826)
83. Schon P, Schrot G, Wanner G, Lubitz W, Witte A. Two-stage model for integration of the lysis protein E of phi X174 into the cell envelope of Escherichia coli. FEMS Microbiol. Rev. 17(1-2), 207-212 (1995).
84. Witte A, Schrot G, Schon P, Lubitz W. Proline 21, a residue within the alpha-helical domain of phiX174 lysis protein E, is required for its function in Escherichia coli. Mol. Microbiol. 26(2), 337-346 (1997). (Pubitemid 27483682)
85. Ronchel MC, Molina L, Witte A et al. Characterization of cell lysis in Pseudomonas putida induced upon expression of heterologous killing genes. Appl. Environ. Microbiol. 64(12), 4904-4911 (1998). (Pubitemid 28557858)
86. Kloos DU, Stratz M, Guttler A, Steffan RJ, Timmis KN. Inducible cell lysis system for the study of natural transformation and environmental fate of DNA released by cell death. J. Bacteriol. 176(23), 7352-7361 (1994). (Pubitemid 24364063)
87. Jechlinger W, Szostak MP, Lubitz W. Cold-sensitive E-lysis systems. Gene 218(1-2), 1-7 (1998). (Pubitemid 28434933)
88. Kwon SR, Nam YK, Kim SK, Kim KH. Protection of tilapia (Oreochromis mosambicus) from edwardsiellosis by vaccination with Edwardsiella tarda ghosts. Fish Shellfish Immunol. 20(4), 621-626 (2006). (Pubitemid 41571257)
89. Perrin P, Morgeaux S. Inactivation of DNA by b-propiolactone. Biologicals 23(3), 207-211 (1995).
90. Haidinger W, Mayr UB, Szostak MP, Resch S, Lubitz W. Escherichia coli ghost production by expression of lysis gene E and Staphylococcal nuclease. Appl. Environ. Microbiol. 69(10), 6106-6113 (2003). (Pubitemid 37280335)
91. Langemann T. Process development for industrial scale bacterial ghost production. University of Vienna, Vienna, Austria (2011).
92. Ifere GO, He Q, Igietseme JU et al. Immunogenicity and protection against genital Chlamydia infection and its complications by a multisubunit candidate vaccine. J. Microbiol. Immunol. Infect. 40(3), 188-200 (2007). (Pubitemid 47518721)
93. Macmillan L, Ifere GO, He Q et al. A recombinant multivalent combination vaccine protects against Chlamydia and genital herpes. FEMS Immunol. Med. Microbiol. 49(1), 46-55 (2007). (Pubitemid 46160586)
94. 2+ ATPase (TBCA2) antigen. Am. J. Trop. Med. Hyg. 81(3), 407-415 (2009).
95. Hobom G, Arnold N, Ruppert A. OmpA fusion proteins for presentation of foreign antigens on the bacterial outer membrane. Dev. Biol. Stand. 84, 255-262 (1995).
96. Jechlinger W, Haidinger W, Paukner S et al. Bacterial ghosts as carrier and targeting systems for antigen delivery. In: Vaccine Delivery Strategies. Dietrich G, Goebel W (Eds). Horizon Scientific Press, Wymondham, Norfolk, UK, 163-184 (2002).
97. Schulman H, Kennedy EP. Localization of membrane-derived oligosaccharides in the outer envelope of Escherichia coli and their occurrence in other Gram-negative bacteria. J. Bacteriol. 137(1), 686-688 (1979). (Pubitemid 9100593)
98. Lubitz W. Bacterial ghosts as carrier and targeting systems. Exp. Opin. Biol. Ther. 1(5), 765-771 (2001). (Pubitemid 33769736)
99. Riedmann EM, Kyd JM, Smith AM et al. Construction of recombinant S-layer proteins (rSbsA) and their expression in bacterial ghosts - a delivery system for the nontypeable Haemophilus influenzae antigen Omp26. FEMS Immunol. Med. Microbiol. 37(2-3), 185-192 (2003). (Pubitemid 36776502)
100. Walcher P, Mayr UB, Azimpour-Tabrizi C et al. Antigen discovery and delivery of subunit vaccines by nonliving bacterial ghost vectors. Expert Rev. Vaccines 3(6), 681-691 (2004). (Pubitemid 39576756)
101. Kuen B, Sleytr UB, Lubitz W. Sequence analysis of the sbsA gene encoding the 130-kDa surface-layer protein of Bacillus stearothermophilus strain PV72. Gene 145(1), 115-120 (1994). (Pubitemid 24224973)
102. Riedmann EM, Lubitz W, McGrath J, Kyd JM, Cripps AW. Effectiveness of engineering the nontypeable Haemophilus influenzae antigen Omp26 as an S-layer fusion in bacterial ghosts as a mucosal vaccine delivery. Hum. Vaccin. 7(Suppl.), 99-107 (2011).
103. Cui X, Duckworth JA, Lubitz P et al. Humoral immune responses in brushtail possums (Trichosurus vulpecula) induced by bacterial ghosts expressing possum zona pellucida 3 protein. Vaccine 28(26), 4268-4274 (2010).
104. Mayrhofer P, Tabrizi CA, Walcher P, Haidinger W, Jechlinger W, Lubitz W. Immobilization of plasmid DNA in bacterial ghosts. J. Control. Release 102(3), 725-735 (2005). (Pubitemid 40170214)
105. Jechlinger W, Azimpour Tabrizi C, Lubitz W, Mayrhofer P. Minicircle DNA immobilized in bacterial ghosts: in vivo production of safe non-viral DNA delivery vehicles. J. Mol. Microbiol. Biotechnol. 8(4), 222-231 (2004). (Pubitemid 41368967)
106. Kudela P, Paukner S, Mayr UB et al. Effective gene transfer to melanoma cells using bacterial ghosts. Cancer Lett. 262(1), 54-63 (2008).
107. Kudela P, Paukner S, Mayr UB et al. Bacterial ghosts as novel efficient targeting vehicles for DNA delivery to the human monocyte-derived dendritic cells. J. Immunother. 28(2), 136-143 (2005). (Pubitemid 40328200)
108. Chen ZY, He CY, Kay MA. Improved production and purification of minicircle DNA vector free of plasmid bacterial sequences and capable of persistent transgene expression in vivo. Hum. Gene Ther. 16(1), 126-131 (2005). (Pubitemid 40250338)
109. Paukner S, Kohl G, Lubitz W. Bacterial ghosts as novel advanced drug delivery systems: antiproliferative activity of loaded doxorubicin in human Caco-2 cells. J. Cont. Rel. 94(1), 63-74 (2004). (Pubitemid 37542378)
110. Furst-Ladani S, Redl H, Haslberger A et al. Bacterial cell envelopes (ghosts) but not S-layers activate human endothelial cells (HUVECs) through sCD14 and LBP mechanism. Vaccine 18(5-6), 440-448 (1999). (Pubitemid 29462600)
111. Kudela P, Koller VJ, Mayr UB, Nepp J, Lubitz W, Barisani-Asenbauer T. Bacterial ghosts as antigen and drug delivery system for ocular surface diseases: effective internalization of bacterial ghosts by human conjunctival epithelial cells. J. Biotechnol. 153(3-4), 167-175 (2011).
112. Paukner S, Stiedl T, Kudela P, Bizik J, Al Laham F, Lubitz W. Bacterial ghosts as a novel advanced targeting system for drug and DNA delivery. Exp. Opin. Drug Deliv. 3(1), 11-22 (2006). (Pubitemid 43056388)
113. Felnerova D, Kudela P, Bizik J et al. T cell-specific immune response induced by bacterial ghosts. Med. Sci. Monit. 10(10), BR362-BR370 (2004). (Pubitemid 39424460)
114. Hensel A, Van Leengoed LA, Szostak M et al. Induction of protective immunity by aerosol or oral application of candidate vaccines in a dose-controlled pig aerosol infection model. J. Biotechnol. 44(1-3), 171-181 (1996). (Pubitemid 26056575)
115. Guan L, Mu W, Champeimont J et al. Iron-regulated lysis of recombinant escherichia coli in host releases protective antigen and confers biological containment. Infect. Immun. 79(7), 2608-2618 (2011).
116. Panthel K, Jechlinger W, Matis A et al. Generation of Helicobacter pylori ghosts by PhiX protein E-mediated inactivation and their evaluation as vaccine candidates. Infect. Immun. 71(1), 109-116 (2003). (Pubitemid 36026010)
117. Eko FO, Ekong E, He Q, Black CM, Igietseme JU. Induction of immune memory by a multisubunit chlamydial vaccine. Vaccine 29(7), 1472-1480 (2011).
118. Talebkhan Y, Bababeik M, Esmaeili M et al. Helicobacter pylori bacterial ghost containing recombinant Omp18 as a putative vaccine. J. Microbiol. Methods 82(3), 334-337 (2010).
119. Eko FO, Talin BA, Lubitz W. Development of a Chlamydia trachomatis bacterial ghost vaccine to fight human blindness. Hum. Vaccin. 4(3), 176-183 (2008).
120. Foxwell AR, Kyd JM, Cripps AW. Mucosal immunization against respiratory bacterial pathogens. Expert Rev. Vaccines 2(4), 551-560 (2003). (Pubitemid 36988485)
121. Baqar S, Bourgeois AL, Schultheiss PJ et al. Safety and immunogenicity of a prototype oral whole-cell killed Campylobacter vaccine administered with a mucosal adjuvant in non-human primates. Vaccine 13(1), 22-28 (1995).
122. Mader HJ, Szostak MP, Hensel A, Lubitz W, Haslberger AG. Endotoxicity does not limit the use of bacterial ghosts as candidate vaccines. Vaccine 15(2), 195-202 (1997). (Pubitemid 27091250)
123. Mayr UB, Kudela P, Atrasheuskaya A, Bukin E, Ignatyev GM, Lubitz W. Rectal single dose immunization of mice with Escherichia coli O157:H7 bacterial ghosts induces efficient humoral and cellular immune responses and protects against the lethal heterologous challenge. Microb. Biotechnol. doi:10.1111/j.1751-7915.2011.00316.x (2011) (Epub ahead of print).
124. Marchart J, Dropmann G, Lechleitner S et al. Pasteurella multocida- and Pasteurella haemolytica-ghosts: new vaccine candidates. Vaccine 21(25-26), 3988-3997 (2003). (Pubitemid 37338227)
125. Gudding R, Lillehaug A, Evensen O. Recent developments in fish vaccinology. Vet. Immunol. Immunopathol. 72(1-2), 203-212 (1999).
126. Plumb JA. Edwardsiella septicaemias In: Fish Diseases and Disorders. Volume 3: Viral Bacterial and Fungal Disorders. Woo PTK, Bruno DW (Eds). CAB International, Wallingford, UK 479-521 (1999).
127. Kwon SR, Nam YK, Kim SK, Kim DS, Kim KH. Generation of Edwardsiella tarda ghosts by bacteriophage PhiX174 lysis gene E. Aquaculture 250(1-2), 16-21 (2005). (Pubitemid 41525580)
128. Hart S, Wrathmell AB, Harris JE, Grayson TH. Gut immunology in fish: a review. Develop. Comparat. Immunol. 12(3), 453-480 (1988).
129. Kwon SR, Lee EH, Nam YK, Kim SK, Kim KH. Efficacy of oral immunization with Edwardsiella tarda ghosts against edwardsiellosis in olive flounder (Paralichthys olivaceus). Aquaculture 269(1-4), 84-88 (2007). (Pubitemid 47058543)
130. Quentel C, Vigneulle M. Antigen uptake and immune responses after oral vaccination. Dev. Biol. Stand. 90, 69-78 (1997).
131. Kwon SR, Kang YJ, Lee DJ et al. Generation of Vibrio anguillarum ghost by coexpression of PhiX 174 lysis E gene and staphylococcal nuclease A gene. Mol. Biotechnol. 42(2), 154-159 (2009).
132. Talwar GP, Vyas HK, Purswani S, Gupta JC. Gonadotropin-releasing hormone/ human chorionic gonadotropin b based recombinant antibodies and vaccines. J. Rep. Immunol. 83(1-2), 158-163 (2009).
133. Purswani S, Talwar GP. Development of a highly immunogenic recombinant candidate vaccine against human chorionic gonadotropin. Vaccine 29(12), 2341-2348 (2011).
134. Lubitz W, Harkness RE, Ishiguro EE. Requirement for a functional host cell autolytic enzyme system for lysis of Escherichia coli by bacteriophage phi X174. J. Bacteriol. 159(1), 385-387 (1984). (Pubitemid 14084990)
135. Wadle D, Henrich B, Plapp R. Effect of mutations in genes fadR, fabB, fadE and envC of Escherichia coli on the action of the lysis gene of bacteriophage PhiX174. Curr. Microbiol. 14, 5 (1986).
136. Maratea D, Young K, Young R. Deletion and fusion analysis of the phage phi X174 lysis gene E. Gene 40(1), 39-46 (1985). (Pubitemid 16132024)
137. Halfmann G. Einfluss zellulaerar mutationen auf die PhiX174 protein E-induzierte lyse von Escherichia coli. University of Munich, Munich, Germany (1989).
138. Witte A, Brand E, Mayrhofer P, Narendja F, Lubitz W. Mutations in cell division proteins FtsZ and FtsA inhibit phiX174 protein-E-mediated lysis of Escherichia coli. Arch. Microbiol. 170(4), 259-268 (1998). (Pubitemid 28430383)
139. Witte A. Untersuchungen zur Wirkung von PhiX174 Protein E sowie davon abgeleiteter chimaerer Protein auf den Zellwandkomplex von Escherichia coli. University of Munich, Munich, Germany (1990).
140. Blasi U, Young R, Lubitz W. Evaluation of the interaction of phi X174 gene products E and K in E-mediated lysis of Escherichia coli. J. Virol. 62(11), 4362-4364 (1988).
141. Zheng Y, Struck DK, Bernhardt TG, Young R. Genetic analysis of MraY inhibition by the phiX174 protein E. Genetics 180(3), 1459-1466 (2008).
142. Abtin A, Kudela P, Mayr UB et al. Escherichia coli ghosts promote innate immune responses in human keratinocytes. Biochem. Biophys. Res. Commun. 400(1), 78-82 (2010).
143. Eko FO, He Q, Brown T et al. A novel recombinant multisubunit vaccine against Chlamydia. J. Immunol. 173(5), 3375-3382 (2004). (Pubitemid 39142047)
144. Wang X, Lu C. Mice orally vaccinated with Edwardsiella tarda ghosts are significantly protected against infection. Vaccine 27(10), 1571-1578 (2009).
145. Chu W, Zhuang X, Lu C. Generation of Aeromonas hydrophila ghosts and their evaluation as oral vaccine candidates in Carassius auratus gibelio. Wei Sheng Wu Xue Bao 48(2), 202-206 (2008).